RETRACTED: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial

A Comparison of Prevention and Treatment of Recurrent Pregnancy Loss with Vaginal Progesterone or Oral Dydrogesterone

“…The risk of miscarriage after 3 miscarriages was 2.4 times higher in the placebo group versus the treatment group (RR 2,4; 95%CI 1,3-5,9, p<0,001). The decrease of miscarriage in the dydrogesterone group (16,8% in the placebo group) was 6,9% and this was highly significant (p<0,004) [3].…”

Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques

“…(23) In a randomised placebo-controlled trial that investigated the effect of dydrogesterone treatment on pregnancy outcomes among women with recurrent miscarriages, the risk of repeat miscarriage was found to be signifi cantly higher (2.4 times) in the placebo group. (25) A study that reviewed birth defects reported from 1977 to 2005 was not able to fi nd any conclusive association between the use of dydrogesterone during pregnancy and congenital birth defects, due to the diversity of birth defects found. (12) Similarly, there was no dominant type of fetal anomaly or any obvious pattern of abnormality among the seven cases of fetal anomalies detected in the present study.…”

A brief guideline proposal for using dydrogesterone prevention or treatment of pregnancy disorders

“…Recent large randomized studies using on the one hand dydrogesterone 20 mg/d up to 20 weeks of gestation [8] and on the other hand a raised dose of micronized progesterone intravaginally of 2 x 400 mg/day up to 12 weeks of gestation [9]. The data for dydrogesterone were leading to a significant reduction of miscarriage, while in the progesterone study there was no significant difference compared with the control group.…”